3Weeratna RD, McCluskie MJ, Comanita L, et al. Optimization strategies for DNA Vaccines. Inter Virol,2000,43:218-226.
4Thermet A, Christine R, Zoulim F, et al. Progress in DNA vaccine for prophylaxis and therapy of hepatitis B. Vaccine, 2003,21:659-662.
5Prince AM, Whalen R, Brotman B, et al. Successful nucleic acid based immunication of newborn chimpanzees against hepatitis B virus. Vaccine,1997,15:916.
6Tacket CO, Roy MJ, Widera G. Phage 1 safety and immune respons e studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine,1999,17:2826-2829.
7Michael ML, Goldbeck C, Pertile T, et al. Immunotherapy of chronic hepatitis B by anti-HBV vaccine: from present to future. Vaccine,2001,19:2395-2399.
8Swain WE, Heydenburg-Fuller D, Wu MS, et al. Tolerability and immune responses in humans to a PowderJect DNA vaccine for hepatitis B. Dev Biol(Basel),2000,104:115-119.
9Haworth R, Pilling AM. The PCR assay in the preclinical safety evaluation of nucleic acid medicines. Hum Exp Toxicol,2000,19:267-276.
10Loirat D, Li Z, Mancini M, et al. Muscle specific expression of HBsAg: no effect on DNA-raised immune response. Virology,1999,260:74-83.
